Core Viewpoint - VolitionRx Limited is sponsoring a symposium at the European Hidradenitis Suppurativa Foundation Conference to present findings on the Nu.Q NETs assay, which aids in the management of Hidradenitis Suppurativa (HS) through a precision medicine approach [1][2][3]. Company Overview - VolitionRx Limited is a multi-national epigenetics company focused on advancing the science of epigenetics and improving outcomes for patients through earlier detection and monitoring of diseases [11][12]. - The company is developing cost-effective blood tests for various diseases, including cancers and conditions associated with NETosis, aiming to enhance patient quality of life [12]. Industry Context - Hidradenitis Suppurativa (HS) is a chronic condition affecting approximately 1% of the global population, characterized by painful skin abscesses and scarring [3][9]. - The condition is difficult to manage, and the introduction of biological treatments has shown varied responses among patients, highlighting the need for a precision medicine approach [4][9]. Product and Market Potential - The Nu.Q NETs assay is CE-Marked for clinical use in 27 EU member states and is positioned as a simple, low-cost test to detect diseases associated with NETosis, with a total addressable market estimated at $3.8 billion [6][8]. - The assay aims to classify HS patients and guide treatment decisions, potentially improving patient management and outcomes [4][6].

For the treatment of aggression and social withdrawal MADRID and CAMBRIDGE, Mass., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a global leader in epigenetics, today announced that it has received a “Decision to grant” communication from the Japanese Patent Office for its patent application JP2023-136283, titled “Methods of treating behavior alterations”, related to vafidemstat, Oryzon’s LSD1 inhibitor in clinical deve ...

HENDERSON, Nev., Jan. 30, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the preparation of the reimbursement submission for its Nu.Q® Cancer assays to government agencies in France. The submission will be actively supported by the Hospices Civils de Lyon (HCL), France's second largest university hospital system, and will run in parallel with the previously announced process to achieve clinical certification of the test at HC ...

Core Insights - VolitionRx Limited has appointed two new centralized laboratory providers for its Nu.Q® Vet Cancer test, enhancing access to its canine cancer early detection tool in the U.S. and Asia [1][7] Company Overview - Volition is a multi-national epigenetics company focused on advancing the science of epigenetics to improve outcomes for people and animals through earlier detection of diseases [3][4] - The company is dedicated to developing cost-effective blood tests for various diseases, including cancers and conditions associated with NETosis, such as sepsis [4] Market Opportunity - The Total Addressable Market (TAM) for the Nu.Q® Vet Cancer test is approximately $100 million across the U.S., Europe, and Japan, which could increase to nearly $150 million with the inclusion of China [3][7] Product Development - The Nu.Q® Canine Cancer Test can be integrated into annual checkups or senior wellness exams, allowing veterinarians to detect cancer earlier and assist pet owners in making informed decisions regarding cancer care [2][4]

Core Insights - VolitionRx Limited is sponsoring an industry symposium at the Veterinary Meeting and Expo (VMX) in Orlando, Florida, where Dr. Sue Ettinger will present on the Nu.Q® Vet Cancer Test [1][2] Company Overview - Volition is a multi-national company focused on advancing epigenetics to improve outcomes for people and animals with life-altering diseases through earlier detection and monitoring [4] - The company is developing cost-effective blood tests for detecting and monitoring various diseases, including cancers and conditions associated with NETosis, such as sepsis [5] Industry Engagement - VMX 2026 is expected to attract approximately 20,000 veterinary professionals, providing a significant platform for Volition to showcase its Nu.Q® Test [3] - The Volition Veterinary Diagnostics Development team will be present at booth 2243 during the conference [3]

Core Viewpoint - VolitionRx Limited has entered into an amended agreement with Lind Global Asset Management to secure $2,000,000 in funding through the issuance of a senior secured convertible promissory note and a common stock purchase warrant, enhancing its financial position for future growth [1][2]. Group 1: Financial Details - The company will issue a senior secured convertible promissory note with a principal amount of $2,400,000 and a common stock purchase warrant to purchase up to 7,000,350 shares at an exercise price of $0.5714 per share [1]. - The 2026 Note will be repaid in eighteen monthly installments of $133,333 starting six months after issuance, with the option for the investor to increase payments up to $1,000,000 for two months [3]. - A commitment fee of $70,000 will be paid to the investor, deducted from the funding received [1]. Group 2: Previous Agreements - The amended agreement updates a previous securities purchase agreement from May 15, 2025, where the company issued a senior secured convertible promissory note of $7,500,000 and a warrant for 13,020,834 shares [2]. - Both the 2025 and 2026 Notes are secured by the assets of the company and its subsidiaries [2]. Group 3: Regulatory Compliance - The company is required to file a registration statement within 30 days of closing to cover the resale of shares issued upon conversion of the 2026 Note or exercise of the 2026 Warrant [4]. Group 4: Company Overview - Volition is a multi-national company focused on advancing epigenetics to improve early detection and monitoring of diseases, including cancers and conditions associated with NETosis [6][7]. - The company's research and development activities are primarily based in Belgium, with additional offices in the U.S. and London [8].

Core Insights - VolitionRx Limited has developed the Nu.Q® Vet Feline assay, achieving 100% specificity and detecting over 80% of feline lymphomas, marking a significant advancement in veterinary cancer diagnostics [1][2][3] Company Overview - Volition is a multi-national epigenetics company focused on early detection of diseases, including cancers, through blood tests [6][7] - The company aims to make cancer screening a routine part of annual wellness checks for pets, having already successfully rolled out a canine cancer test [3][6] Market Opportunity - The introduction of the feline cancer test could potentially double Volition's total addressable market in the companion animal space, as the canine test is already available in over 20 countries [4][5] - There are approximately 73.8 million pet cats in the U.S., with an estimated 1 in 5 cats likely to develop cancer in their lifetime, highlighting a significant market need [5] - The North American veterinary oncology market is projected to reach $1.77 billion by 2025, with the feline segment expected to grow at a faster rate than the canine segment due to increasing owner awareness [5] Product Development and Revenue Potential - The successful publication of the study in a peer-reviewed journal is anticipated to unlock a $5 million contractual milestone payment for Volition [5] - The company is focused on completing product development and making the Nu.Q® Vet Feline Test available through existing distribution networks [3][4]

Core Insights - Oryzon Genomics, a clinical-stage biopharmaceutical company, is a leader in epigenetics and focuses on personalized medicine for CNS disorders and oncology [3] Group 1: Upcoming Events - Oryzon management will participate in the 9th Sachs Annual Neuroscience Innovation Forum on January 11, 2026, in San Francisco, with a presentation scheduled at 10:35 am (PST) [1] - The company will also attend the 44th Annual J.P. Morgan Healthcare Conference from January 12-15, 2026, in San Francisco, and the Allinvest Securities Biomed Forum on January 29, 2026, in Paris, where one-on-one meetings will be available [2] Group 2: Company Overview - Founded in 2000 in Barcelona, Oryzon is recognized as the European leader in epigenetics, with a clinical portfolio that includes two LSD1 inhibitors: vafidemstat (Phase III-ready) for CNS and iadademstat (Phase II) for oncology/hematology [3] - The company is developing other pipeline assets targeting epigenetic mechanisms, including ORY-4001 for potential use in CMT and ALS, and has a robust platform for biomarker identification and target validation across various malignant and neurological diseases [3]

Company Overview - VolitionRx is focused on saving lives and improving outcomes through low-cost testing in cancer, sepsis, and veterinary applications[4, 5] - The company operates with a low capex, low opex business model, emphasizing commercial partnerships and out-licensing[21] - VolitionRx leverages its IP Powerhouse with 56 patent families and a team with hundreds of years of experience[5] Commercialization and Licensing - The company received $10 million upfront and $13 million in milestone payments from an exclusive Element i+ in-house analyzer licensing partnership[29] - In 2024, Volition sold over 120,000 Nu.Q® Vet Cancer Tests & Components[40] - The company is targeting multiple licensing deals in the human space in 2026, focusing on upfront, milestone, and recurring revenue[25] Products and Market - Nu.Q® Vet is available in the United States, Europe, and Asia, detecting 76% of systemic cancers at 97% specificity[38, 40] - The company estimates a $170 million non-regulated animal testing licensing market, a $4 billion lab-developed screening/management market, and a >$3 billion ICU/ED CE Mark/FDA NETosis sales & licensing market[36] - Lung cancer screening and disease management with Nu.Q® is forecasted to reach over 3 million tests by 2035[63]

Core Insights - Oryzon Genomics has received a patent grant from the Japanese Patent Office for its application related to combinations of iadademstat for cancer therapy, which is a significant step in enhancing its patent portfolio [1][2][3] Patent Protection - The granted patent is expected to remain effective until at least 2040, excluding any potential extensions, securing Oryzon's intellectual property in Europe, Japan, Australia, and Russia [2] - Oryzon is actively pursuing corresponding patent applications in other countries to further strengthen its global patent coverage [2] Clinical Development - Iadademstat is being evaluated in combination with immune checkpoint inhibitors, specifically atezolizumab and durvalumab, for the treatment of small cell lung cancer (SCLC) in an ongoing Phase I/II trial sponsored by the U.S. National Cancer Institute [3] - The trial is being conducted at over 30 clinical sites across the U.S., including prestigious institutions like Memorial Sloan Kettering Cancer Center and Johns Hopkins [3] Company Overview - Founded in 2000, Oryzon Genomics is a clinical-stage biopharmaceutical company based in Barcelona, Spain, focusing on epigenetics and personalized medicine in oncology and CNS disorders [4] - The company has a robust clinical portfolio, including two LSD1 inhibitors: vafidemstat (Phase III-ready) and iadademstat (Phase II) [4] Iadademstat Details - Iadademstat (ORY-1001) is a selective inhibitor of the epigenetic enzyme LSD1, showing promising results in hematologic cancers and is currently in various clinical trials for conditions such as acute myeloid leukemia (AML) and small cell lung cancer [5][6] - The drug has demonstrated safety and preliminary efficacy in multiple trials, including a Phase IIa trial in combination with azacitidine for elderly AML patients [5]